LD50 Mouse ip 300 mg/kg, LD50 Mouse sc 750 mg/kg
Pramocaine (also known as pramoxine or pramoxine HCI) is a topical anesthetic and antipruritic. It is used for many dermatological and anorectal/anogenital conditions including minor cuts/burns, insect bites, hives/rashes due to poison ivy exposure, hemorrhoids and other anorectal/anogenital disorders. Pramocaine is available by itself and in combination with other medications in various topical preparations. It works by preventing ionic fluctuations needed for neuron membrane depolarization and action potential propagation.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | Pramocaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Pramocaine. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Pramocaine. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Pramocaine. |
| Hydrocodone | Pramocaine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Pramocaine. |
| Magnesium sulfate | The therapeutic efficacy of Pramocaine can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Pramocaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Pramocaine may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Pramocaine. |
| Mirtazapine | Pramocaine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Pramocaine. |
| Orphenadrine | Pramocaine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Pramocaine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Pramocaine. |
| Pramipexole | Pramocaine may increase the sedative activities of Pramipexole. |
| Ropinirole | Pramocaine may increase the sedative activities of Ropinirole. |
| Rotigotine | Pramocaine may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Pramocaine. |
| Sodium oxybate | The risk or severity of CNS depression can be increased when Sodium oxybate is combined with Pramocaine. |
| Suvorexant | Pramocaine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Pramocaine. |
| Thalidomide | Pramocaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Pramocaine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Pramocaine. |
| Ethanol | Pramocaine may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Pramocaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Pramocaine. |
| Fluvoxamine | The risk or severity of adverse effects can be increased when Pramocaine is combined with Fluvoxamine. |
| Citalopram | The risk or severity of adverse effects can be increased when Pramocaine is combined with Citalopram. |
| Duloxetine | The risk or severity of adverse effects can be increased when Pramocaine is combined with Duloxetine. |
| Trazodone | The risk or severity of adverse effects can be increased when Pramocaine is combined with Trazodone. |
| Paroxetine | The risk or severity of adverse effects can be increased when Pramocaine is combined with Paroxetine. |
| Sertraline | The risk or severity of adverse effects can be increased when Pramocaine is combined with Sertraline. |
| Sibutramine | The risk or severity of adverse effects can be increased when Pramocaine is combined with Sibutramine. |
| Nefazodone | The risk or severity of adverse effects can be increased when Pramocaine is combined with Nefazodone. |
| Escitalopram | The risk or severity of adverse effects can be increased when Pramocaine is combined with Escitalopram. |
| Zimelidine | The risk or severity of adverse effects can be increased when Pramocaine is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when Pramocaine is combined with Dapoxetine. |
| Milnacipran | The risk or severity of adverse effects can be increased when Pramocaine is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of adverse effects can be increased when Pramocaine is combined with Desvenlafaxine. |
| Seproxetine | The risk or severity of adverse effects can be increased when Pramocaine is combined with Seproxetine. |
| Indalpine | The risk or severity of adverse effects can be increased when Pramocaine is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when Pramocaine is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when Pramocaine is combined with Alaproclate. |
| Technetium Tc-99m tilmanocept | Pramocaine may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent. |
| Amitriptyline | The risk or severity of CNS depression can be increased when Amitriptyline is combined with Pramocaine. |
| Olanzapine | The risk or severity of CNS depression can be increased when Olanzapine is combined with Pramocaine. |
| Clozapine | The risk or severity of CNS depression can be increased when Clozapine is combined with Pramocaine. |
| Promazine | The risk or severity of CNS depression can be increased when Promazine is combined with Pramocaine. |
| Cyproheptadine | The risk or severity of CNS depression can be increased when Cyproheptadine is combined with Pramocaine. |
| Imipramine | The risk or severity of CNS depression can be increased when Imipramine is combined with Pramocaine. |
| Chlorpromazine | The risk or severity of CNS depression can be increased when Chlorpromazine is combined with Pramocaine. |
| Gallamine triethiodide | The risk or severity of CNS depression can be increased when Gallamine triethiodide is combined with Pramocaine. |
| Triflupromazine | The risk or severity of CNS depression can be increased when Triflupromazine is combined with Pramocaine. |
| Nortriptyline | The risk or severity of CNS depression can be increased when Nortriptyline is combined with Pramocaine. |
| Amoxapine | The risk or severity of CNS depression can be increased when Amoxapine is combined with Pramocaine. |
| Lamotrigine | The risk or severity of methemoglobinemia can be increased when Lamotrigine is combined with Pramocaine. |
| Rocuronium | The risk or severity of CNS depression can be increased when Rocuronium is combined with Pramocaine. |
| Scopolamine | The risk or severity of CNS depression can be increased when Scopolamine is combined with Pramocaine. |
| Clidinium | The risk or severity of CNS depression can be increased when Clidinium is combined with Pramocaine. |
| Propiomazine | The risk or severity of CNS depression can be increased when Propiomazine is combined with Pramocaine. |
| Brompheniramine | The risk or severity of CNS depression can be increased when Brompheniramine is combined with Pramocaine. |
| Flupentixol | The risk or severity of CNS depression can be increased when Flupentixol is combined with Pramocaine. |
| Cocaine | The risk or severity of methemoglobinemia can be increased when Cocaine is combined with Pramocaine. |
| Quinidine | The risk or severity of methemoglobinemia can be increased when Quinidine is combined with Pramocaine. |
| Maprotiline | The risk or severity of CNS depression can be increased when Maprotiline is combined with Pramocaine. |
| Promethazine | The risk or severity of CNS depression can be increased when Promethazine is combined with Pramocaine. |
| Diphenhydramine | The risk or severity of methemoglobinemia can be increased when Diphenhydramine is combined with Pramocaine. |
| Doxacurium | The risk or severity of CNS depression can be increased when Doxacurium is combined with Pramocaine. |
| Doxepin | The risk or severity of CNS depression can be increased when Doxepin is combined with Pramocaine. |
| Desipramine | The risk or severity of CNS depression can be increased when Desipramine is combined with Pramocaine. |
| Quetiapine | The risk or severity of CNS depression can be increased when Quetiapine is combined with Pramocaine. |
| Mivacurium | The risk or severity of CNS depression can be increased when Mivacurium is combined with Pramocaine. |
| Aripiprazole | The risk or severity of CNS depression can be increased when Aripiprazole is combined with Pramocaine. |
| Chlorprothixene | The risk or severity of CNS depression can be increased when Chlorprothixene is combined with Pramocaine. |
| Metocurine | The risk or severity of CNS depression can be increased when Metocurine is combined with Pramocaine. |
| Pancuronium | The risk or severity of CNS depression can be increased when Pancuronium is combined with Pramocaine. |
| Pipecuronium | The risk or severity of CNS depression can be increased when Pipecuronium is combined with Pramocaine. |
| Rapacuronium | The risk or severity of CNS depression can be increased when Rapacuronium is combined with Pramocaine. |
| Pizotifen | The risk or severity of CNS depression can be increased when Pizotifen is combined with Pramocaine. |
| Benactyzine | The risk or severity of CNS depression can be increased when Benactyzine is combined with Pramocaine. |
| Dosulepin | The risk or severity of CNS depression can be increased when Dosulepin is combined with Pramocaine. |
| Emepronium | The risk or severity of CNS depression can be increased when Pramocaine is combined with Emepronium. |
| Zopiclone | The risk or severity of adverse effects can be increased when Pramocaine is combined with Zopiclone. |
| Botulinum toxin type B | The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with Pramocaine. |
| Botulinum toxin type A | The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Pramocaine. |
| Tryptophan | The risk or severity of CNS depression can be increased when Tryptophan is combined with Pramocaine. |
| Baclofen | Baclofen may increase the central nervous system depressant (CNS depressant) activities of Pramocaine. |
| Lorazepam | The risk or severity of methemoglobinemia can be increased when Lorazepam is combined with Pramocaine. |
| Ethchlorvynol | The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Pramocaine. |
| Succinylcholine | The risk or severity of CNS depression can be increased when Succinylcholine is combined with Pramocaine. |
| Reserpine | The risk or severity of CNS depression can be increased when Reserpine is combined with Pramocaine. |
| Eletriptan | The risk or severity of CNS depression can be increased when Eletriptan is combined with Pramocaine. |
| Enflurane | The risk or severity of CNS depression can be increased when Enflurane is combined with Pramocaine. |
| Temazepam | The risk or severity of CNS depression can be increased when Temazepam is combined with Pramocaine. |
| Reboxetine | The risk or severity of CNS depression can be increased when Reboxetine is combined with Pramocaine. |
| Butabarbital | The risk or severity of CNS depression can be increased when Butabarbital is combined with Pramocaine. |
| Butalbital | The risk or severity of methemoglobinemia can be increased when Butalbital is combined with Pramocaine. |
| Methysergide | The risk or severity of CNS depression can be increased when Methysergide is combined with Pramocaine. |